Lexicon Pharmaceuticals has named Pablo Lapuerta, M.D., chief medical officer. He will be responsible for directing clinical development of Lexicon's drug candidates from phase II proof-of-concept through phase III and approval.

Dr. Lapuerta has 15 years of pharmaceutical industry experience including leadership roles in drug development, global medical affairs and outcomes research strategy across multiple therapeutic areas. Most recently, Lapuerta served as vice president at Bristol-Myers Squibb, where he was responsible for global development of an Alzheimer's disease drug candidate.